A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF SAGE-217 IN THE TREATMENT OF ADULTS WITH SEVERE POSTPARTUM DEPRESSION

Date Added
September 8th, 2020
PRO Number
Pro00101329
Researcher
Constance Guille

List of Studies


Keywords
Obstetrics and Gynecology, Post Partum Depression, Psychiatry
Summary

The main purpose of this study is to determine if treatment with SAGE-217 reduces depressive symptoms in adults with severe postpartum depression (PPD). SAGE-217 is is an investigational drug, which means that it is not yet approved to treat PPD. Participation in the study will last up to 76 days and includes a 14 day treatment period where SAGE-217 is taken by oral pill daily. Visits will take approximately 1 to 3 hours.

Institution
MUSC
Recruitment Contact
Natalie Naylon
843-792-5824
naylon@musc.edu

An Open Label Study to Assess the Feasibility and Tolerability of Accelerated Theta Burst Repetitive Transcranial Magnetic Stimulation (iTBS-rTMS) for the Treatment of Post-Partum Depression

Date Added
January 2nd, 2018
PRO Number
Pro00073886
Researcher
Constance Guille

List of Studies


Keywords
Depression, Post Partum Depression
Summary

This is an open-label study designed to investigate the feasibility and tolerability of a novel TMS treatment protocol to treat depression in women with post-partum depression. It is known that TMS can effectively treat depression. The FDA approved protocol lasts 6 weeks and is not feasible for many women with post-partum depression. We are investigating a 3 day treatment for depression which may be more acceptable for this population. We further hope to characterize the ant-depressant effect of this protocol in order to design a larger trial.

Institution
MUSC
Recruitment Contact
James Fox
843-792-2123 pgr 14687
foxj@musc.edu



-- OR --